Paliperidone, Serum or Plasma
Also known as: PALIPERID
Use
The test is used to optimize drug therapy and monitor patient adherence by detecting paliperidone (9-hydroxyrisperidone) in serum or plasma. The therapeutic range is based on pre-dose (trough) draw at steady state concentration and is intended for clinical purposes. Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension, and dyskinesia.
Special Instructions
The test is not cleared or approved by the US Food and Drug Administration but is performed in a CLIA certified laboratory. For risperidone (parent) and paliperidone (9-hydroxyrisperidone, metabolite), order Risperidone and Metabolite, Serum or Plasma (2007951).
Limitations
The test was developed by ARUP Laboratories and its performance characteristics were determined by them. It is a Laboratory Developed Test (LDT) and thus relies on in-house expertise to provide clinical guidance. It is also worth noting that whole blood, gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution) are unacceptable conditions for specimen collection.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 9383-1
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection.
Patient Preparation
Pre-dose (trough) draw - At steady state concentration.
Storage Instructions
Refrigerated.
Causes for Rejection
Whole blood, gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 weeks |
| Refrigerated | 2 weeks |
| Frozen | 2 months |